$CLVS In a Ph2a trial for Malignant Mesothelioma, Ruca met its primary Endpoint of disease control at 12 wks. DCR12w was 57.7% (95% CI, 36.9 - 76.7). Clinical trial information: NCT03654833.
  • 4
4 Likes